Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

141.39 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,849
Open 141.39
Bid (Size) 141.60 (2)
Ask (Size) 141.66 (2)
Prev. Close 141.39
Today's Range 141.39 - 141.39
52wk Range 77.95 - 148.15
Shares Outstanding N/A
Dividend Yield 1.25%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's Q2 FY24 earnings report on August 8 will include a pre-tax IPR&D charge of... 
Via Benzinga

Performance

YTD
+38.47%
+38.47%
1 Month
+0.73%
+0.73%
3 Month
+14.12%
+14.12%
6 Month
+32.95%
+32.95%
1 Year
+75.69%
+75.69%

More News

Read More
7 Top-Quality Stocks to Buy Now: July 2024
Via InvestorPlace
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
2 Incredibly Cheap Growth Stocks to Buy Now
Via The Motley Fool
Is Eli Lilly a Good Dividend Stock to Buy Now?
Via The Motley Fool
This 1 Piece of Bad News for Novo Nordisk Is Good News for Eli Lilly Stock
Via The Motley Fool
Here's 80 Billion More Reasons to Buy Novo Nordisk Stock
Via The Motley Fool
The 7 Most Important Stocks to Watch as Q2 Earnings Season Kicks Off
Via InvestorPlace
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
Via The Motley Fool
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
Via Talk Markets
Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study
Via Investor's Business Daily
Stock Market Shifts Toward Small Caps After Tame CPI; JPMorgan, Taiwan Semi, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
Via Benzinga
3 Global Stocks Worth Buying as America Stumbles
Via InvestorPlace
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Via Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Via Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Via Benzinga
FDA Rejects Novo Nordisk's Weekly Insulin, Requests Information Related To Manufacturing Process, Type 1 Diabetes
Via Benzinga
Exposures Product Safety
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Via Benzinga
Chipotle Just Did a Stock Split. History Says This Is What Might Happen Next.
Via The Motley Fool
Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
Via Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.